Core Insights - Ardelyx, Inc. is set to present data on its first-in-class retainagogue, IBSRELA (tenapanor), at the Digestive Disease Week Conference, highlighting its approval for treating irritable bowel syndrome with constipation (IBS-C) in adults [1] Company Overview - Ardelyx is focused on discovering, developing, and commercializing innovative medicines that address significant unmet medical needs [11] - The company has two commercial products approved in the U.S.: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [11] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [11] Product Information - IBSRELA (tenapanor) acts as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which helps retain luminal water content, accelerating intestinal transit time and resulting in softer stool consistency [4] - The drug has been shown to reduce abdominal pain by decreasing visceral hypersensitivity and intestinal permeability in animal models [4] - IBSRELA is indicated for the treatment of IBS-C in adults, with a significant patient population of approximately 12 million affected in the U.S. [5][10] Clinical Data Presentation - Ardelyx will sponsor a Product Theater at the conference, focusing on integrating a different mechanism of action into the treatment of IBS-C, featuring clinical considerations and data from two Phase 3 clinical trials [3]